Behaviour change: general approaches (PH6)Product type:GuidanceProgramme:Public health guidelinePublished: 24 October 2007
Behaviour change: individual approaches (PH49)Product type:GuidanceProgramme:Public health guidelinePublished: 2 January 2014
Cardiovascular disease prevention (PH25)Product type:GuidanceProgramme:Public health guidelinePublished: 22 June 2010
CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)Product type:AdviceProgramme:Medtech innovation briefingLast updated: 9 December 2016Published: 22 January 2016
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)Product type:GuidanceProgramme:NICE guidelinePublished: 20 October 2015
Digital technologies for multidisciplinary weight managementStatus:In developmentProgramme:Health technology evaluationExpected publication date: TBC
Endoscopic sleeve gastroplasty for obesity (IPG783)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 February 2024
ID6611 Obesity, overweight - semaglutide (including review of TA875)Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Implantation of a duodenal–jejunal bypass sleeve for managing obesity (IPG471)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 November 2013
Laparoscopic gastric plication for the treatment of severe obesity (IPG432)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 November 2012
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2021
Liraglutide for managing overweight and obesity (TA664)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 December 2020
Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years (NG247)Product type:GuidanceProgramme:NICE guidelinePublished: 15 January 2025
Naltrexone–bupropion for managing overweight and obesity (TA494)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2017
Neonatal parenteral nutrition (NG154)Product type:GuidanceProgramme:NICE guidelinePublished: 26 February 2020
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)Product type:GuidanceProgramme:Clinical guidelineLast updated: 4 August 2017Published: 22 February 2006
Orforglipron for managing overweight and obesity ID6516Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Overweight and obesity management (NG246)Product type:GuidanceProgramme:NICE guidelineLast updated: 8 January 2026Published: 14 January 2025
Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)Product type:Quality standardPublished: 11 May 2018
Retatrutide for managing overweight and obesity [ID6644]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for managing overweight and obesity (TA875)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 4 September 2023Published: 8 March 2023
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2023
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 May 2026
Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 16 January 2026Expected publication date: 10 February 2027
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 22 May 2024
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: 19 August 2026
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 6 July 2022
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2016
Swallowable gastric balloon capsule for weight loss (IPG684)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 18 November 2020
Tirzepatide for managing overweight and obesity (TA1026)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 September 2025Published: 23 December 2024
Vitamin D: supplement use in specific population groups (PH56)Product type:GuidanceProgramme:Public health guidelineLast updated: 30 August 2017Published: 26 November 2014